A comprehensive review on nanocarriers as a targeted delivery system for the treatment of breast cancer
Amreen Fatima, Nazish Naseem, Md Faheem Haider, Md Azizur Rahman, Jyotiraditya Mall, Muhammad Sahil Saifi, Juber Akhtar
A comprehensive review on nanocarriers as a targeted delivery system for the treatment of breast cancer
Breast cancer is the most common malignant tumour in women worldwide, as well as the leading cause of death from malignant tumours. All across the world, the incidence of breast cancer is steadily rising. Although numerous drugs acting through various mechanisms of action are available in the market as conventional formulations for the treatment of breast cancer, they face significant challenges in terms of bioavailability, dosing, and associated adverse effects, which severely limit their therapeutic efficacy. Several studies have shown that nanocarriers can significantly improve the drug’s bioavailability, reducing the need for frequent dosing and reducing the toxicity linked to high drug doses. The current review provides insight into the challenges associated with conventional breast cancer formulations and the need for oral nanoparticulate systems to overcome problems associated with conventional formulations. This review focuses on various topics, such as an in-depth analysis of potential anticancer drugs that have used nanocarrier technology to treat breast cancer successfully.
Cancer / Breast cancer / Bioavailability / Signaling pathway / Nanocarrier
[1] |
Memariani Z, Abbas SQ, Ul Hassan SS, Ahmadi A, Chabra A. Naringin and naringenin as anticancer agents and adjuvants in cancer combination therapy: efficacy and molecular mechanisms of action, a comprehensive narrative review. Pharmacol Res. 2021;171:105264.
CrossRef
Google scholar
|
[2] |
Koene RJ, Prizment AE, Blaes A, Konety SH. Shared risk factors in cardiovascular disease and cancer. Circulation. 2016;133(11):1104–1114.
CrossRef
Google scholar
|
[3] |
Adnan, M., Afzal, O., Altamimi, A.S., Alamri, M.A., Haider, T. and Haider, M.F., Development and optimization of Transethosomal gel of Apigenin for topical delivery: in-vitro, ex-vivo and cell line assessment. Int J Pharm, p.122506. 10.1016/j.ijpharm.2022.122506.
|
[4] |
Shahid A, Khan MM, Ahmad U, Haider MF, Ali A. Exploring liposomes for lung cancer therapy. Crit Rev Ther Drug Carrier Syst. 2022;39(4).
CrossRef
Google scholar
|
[5] |
Eggert JA, Palavanzadeh M, Blanton A. Screening and early detection of lung cancer. InSeminars in oncology nursing. 2017 May 1;33(2):129–140. WB Saunders.
CrossRef
Google scholar
|
[6] |
Henry NL, Shah PD, Haider I, Freer PE, Jagsi R, Sabel MS. Chapter 88: cancer of the breast. In: Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, eds. Abeloff’s Clinical Oncology. 6th ed. Philadelphia, Pa: Elsevier;2020.
|
[7] |
Iacoviello L, Bonaccio M, de Gaetano G, Donati MB. Epidemiology of breast cancer, a paradigm of the “common soil” hypothesis. July Semin Cancer Biol. 2021;72:4–10. Academic Press.
CrossRef
Google scholar
|
[8] |
Alam T, Khan S, Gaba B, Haider MF, Baboota S, Ali J. Nanocarriers as treatment modalities for hypertension. Drug Deliv. 2017;24(1):358–369.
CrossRef
Google scholar
|
[9] |
Sharma GN, Dave R, Sanadya J, Sharma P, Sharma K. Various types and management of breast cancer: an overview. \“J Adv Pharm Technol Research\”\“ (JAPTR)\”. 2010;1(2):109. https://www.japtr.org/text.asp?2010/1/2/109/72251.
CrossRef
Google scholar
|
[10] |
Chen Z, Yang J, Li S, et al. Invasive lobular carcinoma of the breast: a special histological type compared with invasive ductal carcinoma. PLoS One. 2017;12(9): e0182397.
CrossRef
Google scholar
|
[11] |
Martinez SR, Beal SH, Canter RJ, Chen SL, Khatri VP, Bold RJ. Medullary carcinoma of the breast: a population-based perspective. Med Oncol. 2011;28:738–744.
CrossRef
Google scholar
|
[12] |
Rakha EA, Lee AH, Evans AJ, et al. Tubular carcinoma of the breast: further evidence to support its excellent prognosis. J Clin Oncol. 2010;28(1):99–104.
CrossRef
Google scholar
|
[13] |
Stras S. Environmentally Responsive Liposomes for Treatment of Metastatic Triple Negative Breast Cancer. (Doctoral dissertation, Rutgers The State University of New Jersey, School of Graduate Studies);2018.
|
[14] |
Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321(3):288–300. 10.1001/jama.2018.19323.
CrossRef
Google scholar
|
[15] |
Kamdje AHN, Etet PFS, Vecchio L, Muller JM, Krampera M, Lukong KE. Signaling pathways in breast cancer: therapeutic targeting of the microenvironment. Cell Signal. 2014;26(12):2843–2856.
CrossRef
Google scholar
|
[16] |
Ahmad A. Pathways to breast cancer recurrence. Int Sch Res Notices. 2013. 2013.
CrossRef
Google scholar
|
[17] |
Ponde N, Bradbury I, Lambertini M, et al. Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06). Breast Cancer Res Treat. 2018;168:631–638.
CrossRef
Google scholar
|
[18] |
Mehta A, Tripathy D. Co-targeting estrogen receptor and HER2 pathways in breast cancer. Breast. 2014;23(1):2–9.
CrossRef
Google scholar
|
[19] |
Shaw HV, Koval A, Katanaev V. Targeting the Wnt signalling pathway in cancer: prospects and perils. Swiss Med Wkly. 2019;149:w20129. https://doi.org/10.4414/smw.2019.20129.
|
[20] |
Dhankhar R, Vyas SP, Jain AK, Arora S, Rath G, Goyal AK. Advances in novel drug delivery strategies for breast cancer therapy. Artificial Cells, Blood Substitutes. Biotechnology. 2010;38(5):230–249.
CrossRef
Google scholar
|
[21] |
Dranitsaris G, Yu B, Wang L, et al. Abraxane® versus Taxol® for patients with advanced breast cancer: a prospective time and motion analysis from a Chinese health care perspective. J Oncol Pharm Pract. 2016;22(2):205–211.
CrossRef
Google scholar
|
[22] |
Stemmler HJ, Gutschow K, Sommer H, et al. Weekly docetaxel (Taxotere®) in patients with metastatic breast cancer. Ann Oncol. 2001;12(10):1393–1398.
CrossRef
Google scholar
|
[23] |
Paradiso A, Mangia A, Chiriatti A, et al. Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. Ann Oncol. 2005;16: iv14–iv19.
CrossRef
Google scholar
|
[24] |
Seidman AD. Gemcitabine as single-agent therapy in the management of advanced breast cancer. Oncology (Williston Park, NY). 2001;15(2 Supple 3):11–14.
|
[25] |
Hortobagyi GN. Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial. Breast Cancer Res. 2018;20(1):1–11.
CrossRef
Google scholar
|
[26] |
Toogood PL, Ide ND. Palbociclib (Ibrance): the first-in-class CDK4/6 inhibitor for breast cancer. Innovative Drug Synthesis. 2015:167–196.
CrossRef
Google scholar
|
[27] |
Laderian B, Fojo T. CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib. December Semin Oncol. 2017;44(6):395–403. WB Saunders.
CrossRef
Google scholar
|
[28] |
Hu Q, Gong JP, Li J, et al. Down-regulation of miRNA-452 is associated with adriamycin-resistance in breast cancer cells. Asian Pac J Cancer Prev APJCP. 2014;15(13):5137–5142.
CrossRef
Google scholar
|
[29] |
Dank M. The role of aromasin in the hormonal therapy of breast cancer. Pathol Oncol Res. 2002;8:87–92.
CrossRef
Google scholar
|
[30] |
Suzuki N, Shiota T, Watanabe F, et al. Synthesis and evaluation of novel pyrimidine-based dual EGFR/Her-2 inhibitors. Bioorg Med Chem Lett. 2011;21(6):1601–1606.
CrossRef
Google scholar
|
[31] |
Stebbing J, Copson E, O’Reilly S. Herceptin (transzumab) in advanced breast cancer. Cancer Treat Rev. 2000;26(4):287–290.
CrossRef
Google scholar
|
[32] |
Lewis JD, Chagpar AB, Shaughnessy EA, Nurko J, McMasters K, Edwards MJ. Excellent outcomes with adjuvant toremifene or tamoxifen in early-stage breast cancer. Cancer. 2010;116(10):2307–2315.
CrossRef
Google scholar
|
[33] |
Senanayake TH, Warren G, Wei X, Vinogradov SV. Application of activated nucleoside analogs for the treatment of drug-resistant tumors by oral delivery of nanogel-drug conjugates. J Contr Release. 2013;167(2):200–209.
CrossRef
Google scholar
|
[34] |
Depowski PL, Rosenthal SI, Brien TP, Stylos S, Johnson RL, Ross JS. Topoisomerase IIα expression in breast cancer: correlation with outcome variables. Mod Pathol. 2000;13(5):542–547.
CrossRef
Google scholar
|
[35] |
Ogino M, Fujii T, Nakazawa Y, et al. Implications of Topoisomerase (TOP1 and TOP2α) expression in patients with breast cancer. In Vivo. 2020;34(6):3483–3487.
CrossRef
Google scholar
|
[36] |
Kwapisz D. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib. Breast Cancer Res Treat. 2017;166:41–54.
CrossRef
Google scholar
|
[37] |
Brueggemeier RW. Aromatase, aromatase inhibitors, and breast cancer. Am J Therapeut. 2001;8(5):333–344.
CrossRef
Google scholar
|
[38] |
Johnston SR, Dowsett M. Aromatase inhibitors for breast cancer: lessons from the laboratory. Nat Rev Cancer. 2003;3(11):821–831.
CrossRef
Google scholar
|
[39] |
Foa R, Norton L, Seidman AD. Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activity. Int J Clin Lab Res. 1994;24:6–14.
CrossRef
Google scholar
|
[40] |
Peltier S, Oger JM, Lagarce F, Couet W, Benoît JP. Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules. Pharmaceut Res. 2006;23:1243–1250.
CrossRef
Google scholar
|
[41] |
Alven S, Aderibigbe BA. The therapeutic efficacy of dendrimer and micelle formulations for breast cancer treatment. Pharmaceutics. 2020;12(12):1212.
CrossRef
Google scholar
|
[42] |
Zhang E, Xing R, Liu S, Li P. Current advances in development of new docetaxel formulations. Expet Opin Drug Deliv. 2019;16(3):301–312.
CrossRef
Google scholar
|
[43] |
Khan AW, Kotta S, Ansari SH, Sharma RK, Ali J. Enhanced dissolution and bioavailability of grapefruit flavonoid Naringenin by solid dispersion utilizing fourth generation carrier. Drug Dev Ind Pharm. 2015;41(5):772–779.
CrossRef
Google scholar
|
[44] |
Di H, Wu H, Gao Y, Li W, Zou D, Dong C. Doxorubicin-and cisplatin-loaded nanostructured lipid carriers for breast cancer combination chemotherapy. Drug Dev Ind Pharm. 2016;42(12):2038–2043.
CrossRef
Google scholar
|
[45] |
Zango UU, Abubakar A, Saxena R, Arya V. Phyto-nanotechnology: enhancing plant based mediated anticancer chemical therapies. Therapeutic Drug Targets and Phytomedicine for Triple Negative Breast Cancer. 2023:161.
CrossRef
Google scholar
|
[46] |
Nounou MI, ElAmrawy F, Ahmed N, Abdelraouf K, Goda S, Syed-Sha-Qhattal H. Breast cancer: conventional diagnosis and treatment modalities and recent patents and technologies. Breast Cancer Basic Clin Res. 2015;9. BCBCR-S29420.
CrossRef
Google scholar
|
[47] |
Gaba B, Khan T, Haider MF, et al. Vitamin E loaded naringenin nanoemulsion via intranasal delivery for the management of oxidative stress in a 6-OHDA Parkinson’s disease model. BioMed Res Int. 2019;2019.
CrossRef
Google scholar
|
[48] |
Bu H, He X, Zhang Z, Yin Q, Yu H, Li Y. A TPGS-incorporating nanoemulsion of paclitaxel circumvents drug resistance in breast cancer. Int J Pharm. 2014;471(1–2):206–213.
CrossRef
Google scholar
|
[49] |
Alkhatib MH, Bawadud RS, Gashlan HM. Incorporation of docetaxel and thymoquinone in borage nanoemulsion potentiates their antineoplastic activity in breast cancer cells. Sci Rep. 2020;10(1):18124.
CrossRef
Google scholar
|
[50] |
Alkhatib MH, AlBishi HM. In vitro evaluation of antitumor activity of doxorubicinloaded nanoemulsion in MCF-7 human breast cancer cells. J Nanoparticle Res. 2013;15:1–15.
CrossRef
Google scholar
|
[51] |
Natesan S, Sugumaran A, Ponnusamy C, Thiagarajan V, Palanichamy R, Kandasamy R. Chitosan stabilized camptothecinnanoemulsions: development, evaluation and biodistribution in preclinical breast cancer animal mode. Int J Biol Macromol. 2017;104:1846–1852.
CrossRef
Google scholar
|
[52] |
Machado FC, de Matos RPA, Primo FL, Tedesco AC, Rahal P, Calmon MF. Effect of curcumin-nanoemulsion associated with photodynamic therapy in breast adenocarcinoma cell line. Bioorg Med Chem. 2019;27(9):1882–1890.
CrossRef
Google scholar
|
[53] |
Abedinpour N, Ghanbariasad A, Taghinezhad A, Osanloo M. Preparation of nanoemulsions of mentha piperita essential oil and investigation of their cytotoxic effect on human breast cancer lines. BioNanoScience. 2021;11:428–436.
CrossRef
Google scholar
|
[54] |
Ombredane AS, Araujo VH, Borges CO, et al. Nanoemulsion-based systems as a promising approach for enhancing the antitumoral activity of pequi oil (CaryocarbrasilenseCambess.) in breast cancer cells. J Drug Deliv Sci Technol. 2020;58:101819.
CrossRef
Google scholar
|
[55] |
Miranda SEM, de Alcântara Lemos J, Fernandes RS, et al. Enhanced antitumor efficacy of lapachol-loaded nanoemulsion in breast cancer tumor model. Biomed Pharmacother. 2021;133:110936.
CrossRef
Google scholar
|
[56] |
Haider MF, Khan S, Gaba B, et al. Optimization of rivastigmine nanoemulsion for enhanced brain delivery: in-vivo and toxicity evaluation. J Mol Liq. 2018;255:384–396.
CrossRef
Google scholar
|
[57] |
Song X, Zhang Y, Zuo R, et al. Repurposing maduramicin as a novel anticancer and anti-metastasis agent for triple-negative breast cancer as enhanced by nanoemulsion. Int J Pharm. 2022;625:122091.
CrossRef
Google scholar
|
[58] |
Wang W, Chen T, Xu H, et al. Curcumin-loaded solid lipid nanoparticles enhanced anticancer efficiency in breast cancer. Molecules. 2018;23(7):1578.
CrossRef
Google scholar
|
[59] |
Yuan Q, Han J, Cong W, et al. Docetaxel-loaded solid lipid nanoparticles suppress breast cancer cells growth with reduced myelosuppression toxicity. Int J Nanomed. 2014;9:4829, 10.18632%2Faging.103036.
CrossRef
Google scholar
|
[60] |
Baek JS, Na YG, Cho CW. Sustained cytotoxicity of wogonin on breast cancer cells by encapsulation in solid lipid nanoparticles. Nanomaterials. 2018;8(3):159.
CrossRef
Google scholar
|
[61] |
Nayek S, Raghavendra NM, Kumar BS. Development of novel S PC-3 gefitinib lipid nanoparticles for effective drug delivery in breast cancer. Tissue distribution studies and cell cytotoxicity analysis. J Drug Deliv Sci Technol. 2021;61:102073.
CrossRef
Google scholar
|
[62] |
de Sousa Marcial SP, Carneiro G, Leite EA. Lipid-based nanoparticles as drug delivery system for paclitaxel in breast cancer treatment. J Nanoparticle Res. 2017;19:1–11.
CrossRef
Google scholar
|
[63] |
Granja A, Nunes C, Sousa CT, Reis S. Folate receptor-mediated delivery of mitoxantrone-loaded solid lipid nanoparticles to breast cancer cells. Biomed Pharmacother. 2022;154:113525.
CrossRef
Google scholar
|
[64] |
Siram K, Karuppaiah A, Gautam M, Sankar V. Fabrication of hyaluronic acid surface modified solid lipid nanoparticles loaded with imatinib mesylate for targeting human breast cancer MCF-7 cells. J Cluster Sci. 2022:1–11. https://doi.org/10.1007/S10876-022-02265-y.
|
[65] |
De A, Roychowdhury P, Bhuyan NR, et al. Folic acid functionalized Diallyl Trisulfide–solid lipid nanoparticles for targeting triple negative breast cancer. Molecules. 2023;28(3):1393.
CrossRef
Google scholar
|
[66] |
Üner M, Yener G, Ergüven M. Design of colloidal drug carriers of celecoxib for use in treatment of breast cancer and leukaemia. Mater Sci Eng C. 2019;103:109874.
CrossRef
Google scholar
|
[67] |
Alam T, Khan S, Gaba B, Haider MF, Baboota S, Ali J. Adaptation of quality by design-based development of isradipine nanostructured–lipid carrier and its evaluation for in vitro gut permeation and in vivo solubilization fate. J Pharmaceut Sci. 2018;107(11):2914–2926.
CrossRef
Google scholar
|
[68] |
Sun M, Nie S, Pan X, Zhang R, Fan Z, Wang S. Quercetin-nanostructured lipid carriers: Characteristics and anti-breast cancer activities in vitro. Colloids Surf B Biointerfaces. 2014;113:15–24.
CrossRef
Google scholar
|
[69] |
How CW, Rasedee A, Manickam S, Rosli R. Tamoxifen-loaded nanostructured lipid carrier as a drug delivery system: characterization, stability assessment and cytotoxicity. Colloids Surf B Biointerfaces. 2013;112:393–399.
CrossRef
Google scholar
|
[70] |
Ng WK, Saiful Yazan L, Yap LH, Wan Nor Hafiza WAG, How CW, Abdullah R. Thymoquinone-loaded nanostructured lipid carrier exhibited cytotoxicity towards breast cancer cell lines (MDA-MB-231 and MCF-7) and cervical cancer cell lines (HeLa and SiHa). BioMed Res Int.2015. 2015.
CrossRef
Google scholar
|
[71] |
Sabzichi M, Mohammadian J, Mohammadi M, et al. Vitamin D-loaded nanostructured lipid carrier (NLC): a new strategy for enhancing efficacy of doxorubicin in breast cancer treatment. Nutr Cancer. 2017;69(6):840–848.
CrossRef
Google scholar
|
[72] |
Singh A, Neupane YR, Panda BP, Kohli K. Lipid Based nanoformulation of lycopene improves oral delivery: formulation optimization, ex vivo assessment and its efficacy against breast cancer. J Microencapsul. 2017;34(4):416–429.
CrossRef
Google scholar
|
[73] |
Pedro IDR, Almeida OP, Martins HR, et al. Optimization and in vitro/in vivo performance of paclitaxel-loaded nanostructured lipid carriers for breast cancer treatment. J Drug Deliv Sci Technol. 2019;54:101370. https://doi.org/10.1016/j.jconrel.2022.05.034.
CrossRef
Google scholar
|
[74] |
Carvalho FVD, Ribeiro LNDM, Moura LDD, et al. Docetaxel loaded in Copaiba oilnanostructured lipid carriers as a promising DDS for breast cancer treatment. Molecules. 2022;27(24):8838.
CrossRef
Google scholar
|
[75] |
Kim CH, Kim BD, Lee TH, et al. Synergistic co-administration of docetaxel and curcumin to chemo-resistant cancer cells using PEGylated and RIPL peptideconjugated nanostructured lipid carriers. Cancer Nanotechnology. 2022;13(1):1–26.
CrossRef
Google scholar
|
[76] |
Alhalmi A, Amin S, Khan Z, et al. Nanostructured lipid carrier-based Codelivery of raloxifene and naringin: formulation, optimization, in vitro, ex vivo, in vivo assessment, and acute toxicity studies. Pharmaceutics. 2022;14(9):1771.
CrossRef
Google scholar
|
[77] |
Harada M, Iwata C, Saito H, et al. NC-6301, a polymeric micelle rationally optimized for effective release of docetaxel, is potent but is less toxic than native docetaxel in vivo. Int J Nanomed. 2012:2713–2727.
CrossRef
Google scholar
|
[78] |
Gregoriou Y, Gregoriou G, Yilmaz V, et al. Resveratrol loaded polymeric micelles for theranostic targeting of breast cancer cells. Nanotheranostics. 2021;5(1):113.
CrossRef
Google scholar
|
[79] |
Tan L, Ma B, Chen L, Peng J, Qian Z. Toxicity evaluation and anti-tumor study of docetaxel loaded mPEG-polyester micelles for breast cancer therapy. J Biomed Nanotechnol. 2017;13(4):393–408.
CrossRef
Google scholar
|
[80] |
Chu B, Shi S, Li X, et al. Preparation and evaluation of teniposide-loaded polymeric micelles for breast cancer therapy. Int J Pharm. 2016;513(1–2):118–129.
CrossRef
Google scholar
|
[81] |
Ahmad MA, Kareem O, Khushtar M, et al. Neuroinflammation: a potential risk for dementia. Int J Mol Sci. 2022;23(2):616.
CrossRef
Google scholar
|
[82] |
Chowdhury N, Chaudhry S, Hall N, et al. Targeted delivery of doxorubicin liposomes for Her-2+ breast cancer treatment. AAPS PharmSciTech. 2020;21:1–12.
CrossRef
Google scholar
|
[83] |
Ağardan NM, Değim Z, Yılmaz Ş, Altıntaş L, Topal T. Tamoxifen/raloxifene loaded liposomes for oral treatment of breast cancer. J Drug Deliv Sci Technol. 2020;57:101612.
CrossRef
Google scholar
|
[84] |
Elamir A, Ajith S, Sawaftah NA, et al. Ultrasound-triggered herceptin liposomes for breast cancer therapy. Sci Rep. 2021;11(1):1–13..
CrossRef
Google scholar
|
[85] |
Liu Z, Chen K, Davis C, et al. Drug delivery with carbon nanotubes for in vivo cancer treatment. Cancer Res. 2008;68(16):6652–6660.
CrossRef
Google scholar
|
[86] |
Badea MA, Balas M, Prodana M, Cojocaru FG, Ionita D, Dinischiotu A. Carboxyl-functionalized carbon nanotubes loaded with cisplatin promote the inhibition of Pi3K/Akt pathway and suppress the migration of breast cancer cells. Pharmaceutics. 2022;14(2):469.
CrossRef
Google scholar
|
[87] |
Kulhari H, Pooja D, Shrivastava S, et al. Trastuzumab-grafted PAMAM dendrimers for the selective delivery of anticancer drugs to HER2-positive breast cancer. Sci Rep. 2016;6(1):23179.
CrossRef
Google scholar
|
[88] |
Torres-Pérez SA, del Pilar Ramos-Godínez M, Ramón-Gallegos E. Glycosylated onestep PAMAM dendrimers loaded with methotrexate for target therapy in breast cancer cells MDA-MB-231. J Drug Deliv Sci Technol. 2020;58:101769.
CrossRef
Google scholar
|
[89] |
Pandey P, Arya DK, Ramar MK, Chidambaram K, Rajinikanth PS. Engineered nanomaterials as an effective tool for HER2+ breast cancer therapy. Drug Discov Today.2022.
CrossRef
Google scholar
|
[90] |
Kong T, Hao L, Wei Y, Cai X, Zhu B. Doxorubicin conjugated carbon dots as a drug delivery system for human breast cancer therapy. Cell Prolif. 2018;51(5):e12488.
CrossRef
Google scholar
|
[91] |
Zhang H, Sachdev D, Wang C, Hubel A, Gaillard-Kelly M, Yee D. Detection and downregulation of type I IGF receptor expression by antibody-conjugated quantum dots in breast cancer cells. Breast Cancer Res Treat. 2009;114:277–285.
CrossRef
Google scholar
|
[92] |
Shenoy DB, Amiji MM. Poly (ethylene oxide)-modified poly (ϵ-caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer. Int J Pharm. 2005;293(1–2):261–270.
CrossRef
Google scholar
|
[93] |
Ranade AA, Joshi DA, Phadke GK, et al. Clinical and economic implications of the use of nanoparticle paclitaxel (Nanoxel) in India. Ann Oncol. 2013;24:v6–v12.
CrossRef
Google scholar
|
[94] |
Haider MD, Kanoujia J, Tripathi CB, Arya M, Kaithwas G, Saraf SA. Pioglitazone loaded vesicular carriers for anti-diabetic activity: development and optimization as per central composite design. Journal of Pharmaceutical Sciences and Pharmacology. 2015;2(1):11–20.
CrossRef
Google scholar
|
[95] |
Almoustafa HA, Alshawsh MA, Al-Suede FSR, Alshehade SA, Abdul Majid AMS, Chik Z. The chemotherapeutic efficacy of hyaluronic acid coated polymeric nanoparticles against breast cancer metastasis in Female NCr-Nu/Nu Nude mice. Polymers. 2023;15(2):284.
CrossRef
Google scholar
|
[96] |
Yıldırım M, Acet Ö, Yetkin D, Acet BÖ, Karakoç V, Odabası M. Anti-cancer activity of naringenin loaded smart polymeric nanoparticles in breast cancer. J Drug Deliv Sci Technol. 2022;74:103552.
CrossRef
Google scholar
|
[97] |
Mehrotra N, Anees M, Tiwari S, Kharbanda S, Singh H. Polylactic acid based polymeric nanoparticle mediated co-delivery of navitoclax and decitabine for cancer therapy. Nanomed Nanotechnol Biol Med. 2023;47:102627.
CrossRef
Google scholar
|
[98] |
Conte C, Longobardi G, Barbieri A, et al. Non-covalent strategies to functionalize polymeric nanoparticles with NGR peptides for targeting breast cancer. Int J Pharm. 2023:122618.
CrossRef
Google scholar
|
[99] |
Prasad bn, padmesh tvn, suganya k, govindaraju k, kumar vg, anand kv. Structural and optical properties of water-soluble iron nanoparticles using mimosa pudica leaf extract via green route. University politehnica of bucharest scientific bulletin series bchemistry and materials science. 2016;78(2):177–184.
|
[100] |
Al-Radadi NS. Green biosynthesis of flaxseed gold nanoparticles (Au-NPs) as potent anti-cancer agent against breast cancer cells. J Saudi Chem Soc. 2021;25(6):101243.
CrossRef
Google scholar
|
[101] |
Khodashenas B, Ardjmand M, Rad AS, Esfahani MR. Gelatin-coated gold nanoparticles as an effective pH-sensitive methotrexate drug delivery system for breast cancer treatment. Mater Today Chem. 2021;20:100474.
CrossRef
Google scholar
|
[102] |
Chaudhari R, Nasra S, Meghani N, Kumar A. MiR-206 conjugated gold nanoparticle based targeted therapy in breast cancer cells. Sci Rep. 2022;12(1):4713.
CrossRef
Google scholar
|
[103] |
Kang KW, Chun MK, Kim O, et al. Doxorubicin-loaded solid lipid nanoparticles to overcome multidrug resistance in cancer therapy. Nanomed Nanotechnol Biol Med. 2010;6(2):210–213.
CrossRef
Google scholar
|
[104] |
Kelidari HR, Alipanah H, Roozitalab G, Ebrahimi M, Osanloo M. Anticancer effect of solid-lipid nanoparticles containing Mentha longifolia and Mentha pulegium essential oils: in vitro study on human melanoma and breast cancer cell lines. Biointerface Research in Applied Chemistry. 2022;12(2):2128–2137.
CrossRef
Google scholar
|
[105] |
Goyal P, Goyal K, Kumar SV, Singh AOMPK, Katare OP, Mishra DN. Liposomal drug delivery systems–clinical applications. Acta Pharm. 2005;55(1):1–25.
|
[106] |
Wong MY, Chiu GN. Simultaneous liposomal delivery of quercetin and vincristine for enhanced estrogen-receptor-negative breast cancer treatment. Anti Cancer Drugs. 2010;21(4):401–410.
CrossRef
Google scholar
|
[107] |
Khan Zoya,
|
[108] |
Adnan M, Akhter MH, Afzal O, et al. Exploring nanocarriers as treatment modalities for Skin cancer. Molecules. 2023;28(15):5905.
CrossRef
Google scholar
|
[109] |
Soe ZC, Kwon JB, Thapa RK, et al. Transferrin-conjugated polymeric nanoparticle for receptor-mediated delivery of doxorubicin in doxorubicin-resistant breast cancer cells. Pharmaceutics. 2019;11(2):63.
CrossRef
Google scholar
|
[110] |
Adnan M, Haider MF, Naseem N, Haider T. Transethosomes: a promising challenge for topical delivery Short Title: Transethosomes for topical delivery. Drug Research. 2023;73(4):200–212.
CrossRef
Google scholar
|
[111] |
Kamel AE, Fadel M, Louis D. Curcumin-loaded nanostructured lipid carriers prepared using Peceol™ and olive oil in photodynamic therapy: development and application in breast cancer cell line. Int J Nanomed;2019:5073–5085. https://www.dovepress.com/by146.185.203.38. Accessed July 14, 2019.
CrossRef
Google scholar
|
[112] |
Srivastava S, Haider MF, Ahmad A, Ahmad U, Arif M, Ali A. Exploring nanoemulsions for prostate cancer therapy. Drug Research. 2021;71(8):417–428.
CrossRef
Google scholar
|
[113] |
Uppal S, Sharma P, Kumar R, Kaur K, Bhatia A, Mehta SK. Effect of benzyl isothiocyanate encapsulated biocompatible nanoemulsion prepared via ultrasonication on microbial strains and breast cancer cell line MDA MB 231. Colloids Surf A Physicochem Eng Asp. 2020;596:124732.
CrossRef
Google scholar
|
/
〈 | 〉 |